Paris-based Rivercell raises $25M seed led by HV to build its AI Virtual Cell model that predicts how human cells respond to drugs. Explore how it works.
The TAURUS-1980 Phase I study has dosed its first participants, testing AV-1980R as a preventive tau vaccine. Read what researchers will assess next.
Tempus expands its collaboration with Moderna and Merck to support potential commercialization of a personalized cancer ...
Ultragenyx agreed to sell a rare pediatric disease priority review voucher for $210 million after GENGLYCOS approval. Explore ...
FDA approves Rhapsido (remibrutinib) for adults with symptomatic dermographism beyond CSU. Get the full details on this newly ...
AmyriAD Therapeutics acquires Recognify Life Sciences in an all-share deal to gain RL-007 (inidascamine), a pro-cognitive candidate. Read full details.
Viatris agrees to acquire Pacira BioSciences in a $1.65B all-cash deal at $36.50 per share. Read how this non-opioid pain ...
The FDA approved Pfizer's Tukysa with trastuzumab and pertuzumab for HER2-positive breast cancer maintenance. Find out what ...
Biohaven grants Ono Pharma exclusive rights to its MoDE pan-IgG degrader portfolio in Japan and Asia, with $80M upfront. Read the full deal details now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results